{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/alopecia-androgenetic-male/diagnosis/differential-diagnosis/","result":{"pageContext":{"chapter":{"id":"afbd97db-7525-51a6-aafe-6e937f1cc3e1","slug":"differential-diagnosis","fullItemName":"Differential diagnosis","depth":2,"htmlHeader":"<!-- begin field b1dde3a2-c002-4495-9b5e-c5268e79fe19 --><h2>What else might it be?</h2><!-- end field b1dde3a2-c002-4495-9b5e-c5268e79fe19 -->","summary":"","htmlStringContent":"<!-- begin item fdb27b3e-983b-4099-b0b5-610bd9085ef9 --><!-- begin field 94e4c8bd-4da8-40e2-95f9-6d5cf29ab7f8 --><ul><li><strong>Conditions that may present similarly which cause non-scarring alopecia include:</strong><ul><li><strong>Telogen effluvium</strong> — this is the most common alternative diagnosis. <ul><li>Sudden and severe shedding may occur when a higher percentage of hairs are in the resting phase.</li><li>Shedding may follow significant events — it may occur up to 3 months after childbirth, severe infection, excessive diets, or major surgery, or may be precipitated by some medications (for example antidepressants, anticoagulants, and chemotherapy).</li><li>Usually scalp coverage is good, because more than half the hair must be lost before it is objectively apparent.</li><li>In the active phase, the <a class=\"topic-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/diagnosis/diagnosis-assessment/#pull-test\">pull test</a> may be positive. Later, regrowth with tapered short hairs may be seen.</li></ul></li><li><strong>Alopecia areata</strong> — characterised by diffuse, patchy hair shedding in sharply defined areas. It usually affects women over 40 years of age rather than men. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/alopecia-areata/\">Alopecia areata</a> for more information.</li><li><strong>Syphilis </strong>— characterized by patchy hair loss of the scalp and lateral eyebrows described as having a 'moth-eaten' appearance. These features usually persist for a few weeks and heal spontaneously with or without treatment. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/syphilis/\">Syphilis</a> for more information.</li><li><strong>Traction alopecia</strong> — such as from hair being persistently pulled back in styles like a ponytail.</li><li><strong>Trichotillomania</strong> — a psychiatric condition in which people pull their hair out. It may be associated with obsessive-compulsive disorder and is more common in females than males. Hair loss is asymmetrical and has an unusual shape. Single or multiple areas can be affected, including eyebrows and eyelashes.</li><li><strong>Hair fragility from chemical application </strong>— such as bleaching.</li></ul></li><li><strong>Conditions that present with inflammation, papules, pustules, or scaling on the scalp, may indicate a scarring-type alopecia such as:</strong><ul><li><strong>Discoid lupus erythematosus</strong> — characterized by persistent scaly, disc-like plaques on the scalp, face, and ears that may cause violaceous or pink erythema, scarring, and hair loss.</li><li><strong>Dermatomyositis</strong> — a rare acquired inflammatory myopathy that is accompanied by an itchy skin rash. Although a scaly scalp with hair thinning may occur, it is usually characterized by reddish or bluish-purple patches, mostly on sun-exposed areas of the body.</li><li><strong>Tinea capitis</strong> — typical features include an itchy scaly scalp with patchy, irregular hair loss. Lymphadenopathy (post-auricular and cervical) is often a sign of inflammatory tinea capitis and in more severe cases, erythema, pustules, permanent alopecia, and scarring of hair follicles may occur. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/fungal-skin-infection-scalp/\">Fungal skin infection - scalp</a> for more information.</li></ul></li><li><strong>Other underlying causes of hair loss (less common in men than women) include:</strong><ul><li><strong>Hypothyroidism</strong> and other endocrine disorders, such as hyperprolactinaemia. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypothyroidism/\">Hypothyroidism</a> for more information.</li><li><strong>Iron deficiency</strong> and poor nutritional status.</li><li><strong>Drugs,</strong> including those:<ul><li>Implicated in <a class=\"topic-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/diagnosis/differential-diagnosis/\">telogen effluvium</a>.</li><li>With an androgenic effect (such as anabolic steroids).</li><li>With an antithyroid action (such as carbimazole).</li></ul></li><li><strong>Other systemic disease</strong>, such as a recent severe infection, systemic lupus erythematosus, or cancer.</li></ul></li></ul><!-- end field 94e4c8bd-4da8-40e2-95f9-6d5cf29ab7f8 --><!-- end item fdb27b3e-983b-4099-b0b5-610bd9085ef9 -->","topic":{"id":"5f58d6a9-7ba5-59ad-b7d6-e461768e2621","topicId":"c4dc3303-ee1d-42aa-8da5-078adb684e06","topicName":"Alopecia, androgenetic - male","slug":"alopecia-androgenetic-male","lastRevised":"Last revised in July 2018","chapters":[{"id":"e3fc5b8b-475e-5a1f-a596-104fbf00064f","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"c40b9d81-bd18-5ef2-8284-4c4e6005d65c","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"d860e13e-49f1-54f2-872f-2f3439f27003","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"bbc072f8-3fd9-5a1c-b94c-a0e4fd6edc2f","slug":"changes","fullItemName":"Changes"},{"id":"746928be-2acf-5ae9-9f81-02a942d56a15","slug":"update","fullItemName":"Update"}]},{"id":"3f6cf011-8136-5f24-8cce-31a439cce866","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"5e802365-89ef-5f47-a758-6c880bb456ac","slug":"goals","fullItemName":"Goals"},{"id":"9ed869e3-e3ae-56e1-ae20-0a46d6e20fa2","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d90f156b-7429-5580-b4c3-e50d840d1c8a","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c879d8ad-590c-56af-9685-9eb9a2e30d54","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9e4f37dc-4cc8-5e88-a803-5ca32ca17da9","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"5df134be-2105-5321-86a8-71ed6dca8ebb","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"8a3725c2-b01f-5dd8-a319-33387b40d0ee","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"762358f6-f003-57e8-97ff-1c81299e9364","slug":"definition","fullItemName":"Definition"},{"id":"9ee0c90d-fd96-523f-8f6f-7a26ec56b9c7","slug":"prognosis","fullItemName":"Prognosis"},{"id":"55784b07-7a42-5c0b-9ff3-e9c83216cb1e","slug":"complications","fullItemName":"Complications"},{"id":"7cde82a5-0086-5e04-a669-ec49787685f0","slug":"prevalence","fullItemName":"Prevalence"},{"id":"33fac4d7-a95d-526c-936a-6983e3a12d95","slug":"causes","fullItemName":"Causes"},{"id":"84f86e20-aa91-5e2b-b0b6-bb3cfbf655d6","slug":"risk-factors","fullItemName":"Risk factors"}]},{"id":"4b1bf49e-974e-517b-abd6-59b7ea701502","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"486adc7a-b20b-584e-b20c-1408c8f2dc42","slug":"diagnosis-assessment","fullItemName":"Diagnosis and assessment"},{"id":"afbd97db-7525-51a6-aafe-6e937f1cc3e1","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"4fa73515-d20e-5178-9d6b-eebf5ae2d527","slug":"investigations","fullItemName":"Investigations"}]},{"id":"622bcbbb-d3de-5b15-9b55-ddc4eff327ab","fullItemName":"Management","slug":"management","subChapters":[{"id":"18247780-bdd9-5da4-9d33-1bcf2a883881","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"37e93d68-3a6a-5889-a376-afa236d390aa","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"baab0697-37a1-5edf-88ac-cfb6e2e5656b","slug":"topical-minoxidil-2percent-5percent","fullItemName":"Topical minoxidil 2% and 5%"},{"id":"c42ae7ac-8352-5cac-874c-69c24b99081b","slug":"finasteride","fullItemName":"Finasteride"}]},{"id":"b22c3dba-eb5b-5afa-8f70-43908da7e430","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"444a2a47-2816-5baa-928f-c2bc1b56af85","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"1d1c173f-70b1-5d42-916a-a0bcb5c3557c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"531d7be1-4263-5fd6-a49b-a920a3aaca95","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"dede1c7c-59ec-550c-be37-91849715881e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ddffa446-a263-56e2-a985-c07fa5d06760","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"3b6f4b5d-c7dd-5142-a6e8-2741d9019ade","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0b9ed9ca-1edc-5d61-938a-a6abc5daa77a","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"4b1bf49e-974e-517b-abd6-59b7ea701502","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"6686f446-cea5-54ba-8b04-323d0ff75b4f","slug":"basis-for-recommendation-68a","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field ba68975e-d5cc-4efa-9a74-d67df772f067 --><h3>Basis for recommendation</h3><!-- end field ba68975e-d5cc-4efa-9a74-d67df772f067 -->","summary":null,"htmlStringContent":"<!-- begin item 68a32ff4-20b3-4b66-b21c-17612a0817bd --><!-- begin field cec01089-19b5-4e70-a7a7-ddd62214ea3f --><p>The information on differential diagnoses is based on expert opinion in a European consensus guideline on the diagnostic evaluation of androgenetic alopecia in men, women, and adolescents [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Blume-Peytavi et al, 2010</a>], review articles on the diagnosis and management of androgenetic alopecia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Hillman and Blume-Peytavi, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">Piraccini and Alessandrini, 2014</a>], and the British Medical Journal (BMJ) Best practice article on androgenetic alopecia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/alopecia-androgenetic-male/references/\">BMJ, 2015</a>].</p><!-- end field cec01089-19b5-4e70-a7a7-ddd62214ea3f --><!-- end item 68a32ff4-20b3-4b66-b21c-17612a0817bd -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}